Latest Breaking News On - Hanmi pharmaceutical commits investment - Page 1 : comparemela.com

            ─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc.

Soult ukpyolsiSouth koreaUnited statesAptose biosciencesSusan pietropaoloAptose biosciences incHanmi pharmaceutical incCorporate communications investor relationsToronto stock exchangeAmerican society of hematologyEuropean school of haematologyExchange commissionResponse rateVenetoclax doubletEvaluable patientsPatients who failed prior venetoclax